Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCL

Video

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Peter Martin, MD, chief of the Lymphoma Program at the Meyer Cancer Center and an associate professor of medicine at Weill Cornell Medicine, discusses selecting treatment for patients with high-risk mantle cell lymphoma (MCL).

This patient population does not do well with chemotherapy or targeted therapy, Martin says. Some data have indicated that CAR T-cell therapies have demonstrated activity in patients with blastoid disease, although more time is needed to understand how these products may best be utilized. In diffuse large B-cell lymphoma, CAR T cells are being underutilized relevant to their potential benefit; this may also be true for MCL, Martin explains.

When patients with MCL begin progressing after multiple lines of therapy and BTK inhibitors, the progression can be so rapid that they may not live long enough to receive CAR T-cell therapy, Martin says. As such, it is important to consider when this modality should be used in this patient population, according to Martin. 

If a patient has an aggressive lymphoma with short prior responses to therapy, blastoid histology, or high Ki-67 when starting treatment with a BTK inhibitor, it is important to consider that responses may be transient or suboptimal, Martin notes.

Additionally, CAR T cells should be manufactured when treatment is beginning to minimize any delays in subsequent treatments, Martin concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.